Traditionally, HER2 positive (HER2+) breast cancers were treated with conventional cytotoxic chemotherapy and carried moderate survival outcomes [5], however the advent of Trastuzumab has revolutionised modern oncological practice for this disease, with outcomes comparable to even the most favourable of luminal breast cancers [6]. The gene discussed is ERBB2; the disease is breast carcinoma.